The Ebola vaccine projects – EBOVAC1, EBOVAC2, EBOVAC3, EBODAC and EBOMAN – are among the projects funded under the IMI Ebola+ programme that was launched in response to the Ebola Virus Disease outbreak in West Africa from 2014-2016.

The Executive Steering Committee is common to all Ebola+ projects in which the Janssen Pharmaceutical Companies of Johnson & Johnson is participating, and makes high-level decisions.

The Clinical Steering Committee, which is common to the EBOVAC1, EBOVAC2 and EBOVAC3 projects, makes high-level decisions and approvals regarding implementation strategies.

The separate EBOVAC1, EBOVAC2 and EBOVAC3 Management Committees and the EBODAC Executive Committee are in charge of the overall steering (contractual, clinical and scientific) of the projects in line with the decisions made by the Clinical Steering Committee, the Executive Steering Committee and the advice provided by the following Independent Advisory Boards.

The Scientific Advisory Board is a consultative body composed of independent inter-disciplinary scientific experts whose role is to provide scientific advice to all projects funded under the Ebola+ programme to ensure maximum impact in scientific, technological and health terms for all concerned parties.

The Ethics Board provides advice on any ethical considerations that may arise. It has a consultative role and is asked, where and when relevant, to attend project meetings.